Inactivation of the Cdkn2a locus cooperates with HMGA1 to drive T-cell leukemogenesis

Leukemia and Lymphoma

Volumn 54, Issue 8, 2013, Pages 1762-1768

  Di Cello, Francescopaolo ^a   Dhara, Surajit ^a,d   Hristov, Alexandra C ^a   Kowalski, Jeanne ^a   Elbahloul, Ossama ^a   Hillion, Joelle ^a   Roy, Sujayita ^a   Meijerink, Jules P P ^b   Winter, Stuart S ^c   Larson, Richard S ^c   Huso, David L ^a   Resar, Linda ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF BIOMEDICAL GENOMICS   (India)

Author keywords

HMGA1; Mouse models; T cell acute leukemia

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; HIGH MOBILITY GROUP A1A PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER TRANSPLANTATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE LOCUS; GENE OVEREXPRESSION; IMMUNOPHENOTYPING; LEUKEMIA CELL; LEUKEMOGENESIS; LOSS OF FUNCTION MUTATION; MALE; MOUSE; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; SPLEEN SIZE; T CELL LEUKEMIA; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; EPISTASIS, GENETIC; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC LOCI; HMGA1A PROTEIN; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, T-CELL; MALE; MICE; MICE, KNOCKOUT;

EID: 84877063382     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.764422     Document Type: Article

References (52)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008 ; 371 : 1030-1043
2. Ferrando AA, Look AT. Gene expression profi ling in T-cell acute lymphoblastic leukemia. Semin Hematol 2003; 40: 274-280
3. Grabher C, von Boehmer H, Look A T. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 2006; 6: 347-359
4. Winter SS, Jiang Z, Khawaja HM, et al. Identifi cation of genomic classifi ers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: A report from the children s oncology group. Blood 2007 ; 110 : 1429-1438
5. Andersson A, Ritz C, Lindgren D, et al. Microarray-based classifi cation of a consecutive series of 121 childhood acute leukemias: Prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007 ; 21 : 1198-1203
6. Homminga I, Pieters R, Langerak AW, et al. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell 2011 ; 19 : 484-497
7. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163
8. Meijerink J P. Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2010 ; 23 : 307-318
9. Krug U, Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 2002 ; 21 : 3475-3495
10. Lowe SW, Sherr CJ. Tumor suppression by Ink4a-Arf: Progress and puzzles. Curr Opin Genet Dev 2003; 13: 77-83
11. Cleveland J L, Sherr C J. Antagonism of myc functions by arf. Cancer Cell 2004 ; 6 : 309-311
12. Kees UR, Burton PR, Lu C, et al. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated withunfavorable clinical outcome. Blood 1997 ; 89 : 4161-4166
13. Zhou M, Gu L, Yeager AM, et al. Incidence and clinical signifi cance of CDKN2/MTS1/P16ink4A and MTS2/P15ink4B gene deletions in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1997 ; 14 : 141-150
14. Reeves R. Molecular biology of HMGA proteins: Hubs of nuclear function. Gene 2001 ; 277 : 63-81
15. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007 ; 7 : 899-910
16. Resar LM. The high mobility group A1 gene: Transforming inflammatory signals into cancer? Cancer Res 2010; 70: 436-439
17. Shah SN, Resar LM. High mobility group A1 and cancer: Potential biomarker and therapeutic target. Histol Histopathol 2012 ; 27 : 567-579
18. Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008 ; 40 : 499-507
19. Chou BK, Mali P, Huang X, et al. Effi cient human iPS cell derivation by a non-integrating plasmid from blood cells withunique epigenetic and gene expression signatures. Cell Res 2011; 21: 518-529
20. Zhou G, Chen J, Lee S, et a l. The pattern of gene expression in human CD34 (-) stem/progenitor cells. Proc Natl Acad Sci USA 2001 ; 98 : 13966-13971
21. Karp JE, Smith BD, Resar LS, et al. Phase 1 and pharmacokinetic study of bolus-infusion fl avopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 2011 ; 117 : 3302-3310
22. Nelson DM, Joseph B, Hillion J, et al. Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma 2011; 52: 1999-2006
23. Somervaille T C, Matheny C J, Spencer G J, et a l. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared wiThembryonic rather than adult stem cells. Cell Stem Cell 2009 ; 4 : 129-140
24. Wood LJ, Mukherjee M, Dolde CE, et al. HMG-I/Y, anew c-myc target gene and potential oncogene. Mol Cell Biol 2000 ; 20 : 5490-5502
25. Wood LJ, Maher JF, Bunton TE, et al. The oncogenic properties of the HMG-I gene family. Cancer Res 2000 ; 60 : 4256-4261
26. Dolde CE, Mukherjee M, Cho C, et al. HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat 2002; 71: 181-191
27. Xu Y, Sumter TF, Bhattacharya R, et al. The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res 2004 ; 64 : 3371-3375
28. Tesfaye A, Di Cello F, Hillion J, et a l. The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res 2007; 67: 3998-4004
29. Di Cello F, Hillion J, Hristov A, et al. HMGA2 participates in transformation in human lung cancer. Mol Cancer Res 2008 ; 6 : 743-750
30. Di Cello F, Hillion J, Kowalski J, et al. Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts. Mol Cancer Ther 2008 ; 7 : 2090-2095
31. Hillion J, Dhara S, Sumter TF, et al. The high-mobility group A1a/ signal transducer and activator of transcription-3 axis: An achilles heel for hematopoietic malignancies? Cancer Res 2008; 68: 10121-10127
32. Hillion J, Wood LJ, Mukherjee M, et al. Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res 2009; 7: 1803-1812
33. Hristov AC, Cope L, Reyes MD, et al. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol 2009; 22: 43-49
34. Hristov AC, Cope L, Di Cello F, et al. HMGA1 correlates withadvanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol 2010; 23: 98-104
35. Schuldenfrei A, Belton A, Kowalski J, et a l. HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. BMC Genomics 2011; 12: 549
36. Belton A, Gabrovsky A, Bae YK, et al. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One 2012; 7 : E30034
37. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002 ; 415 : 436-442
38. Fedele M, Pentimalli F, Baldassarre G, et al. Transgenic mice overexpressing the wild-Type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 2005 ; 24 : 3427-3435
39. Battista S, Pentimalli F, Baldassarre G, et a l. Loss of Hmga1 gene function aff ects embryonic stem cell lympho-hematopoietic differentiation. FASEB J 2003 ; 17 : 1496-1498
40. Fedele M, Fidanza V, Battista S, et al. Haploinsuffi ciency of the Hmga1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res 2006; 66: 2536-2543
41. Ikeda K, Mason P J, Bessler M. 3 'UTR-Truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growthadvantage at the level of HSC in mice. Blood 2011; 117: 5860-5869
42. Resar LM, Brodsky RA. " Let " -ing go with clonal expansion? Blood 2011;117:5788-5790
43. Serrano M, Lee H, Chin L, et a l. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996 ; 85 : 27-37
44. Morse HC 3rd, Anver MR, Fredrickson TN, et al. Bethesda proposals for classifi cation of lymphoid neoplasms in mice. Blood 2002 ; 100 : 246-258
45. Herman J G, Civin C I, Issa J P, et a l. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 1997; 57: 837-841
46. Cashen AF, Schiller GJ, O Donnell MR, et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients withacute myeloid leukemia. J Clin Oncol 2010 ; 28 : 556-561
47. Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated withaccumulation of p53 and p16INK4a. Cell 1997 ; 88 : 593-602
48. Secchiero P, Bosco R, Celeghini C, et al. Recent advances in the therapeutic perspectives of nutlin-3. Curr Pharm Des 2011; 17: 569-577
49. Della Gatta G, Palomero T, Perez-Garcia A, et al. Reverse engineering of TLX oncogenic transcriptional networks identifi es RUNX1 as tumor suppressor in T-ALL. Nat Med 2012 ; 18 : 436-440
50. Shah S N, Kerr C, Cope L, et a l. HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. PLoS One 2012; 7 : E48533
51. Hillion J, Smail SS, Di Cello F, et al. The HMGA1-COX-2 axis: A key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology 2012 ; 12 : 372-379
52. Beckerbauer L, Tepe J J, Cullison J, et a l. F R900482 class of anti-Tumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo. Chem Biol 2000 ; 7 : 805-812